PepJunkie Home of the Peptonauts
More

Peptide Atlas · Peptide

Leuprolide (Leuprorelin)

Leuprorelin (leuprolide acetate) is a GnRH analogue that causes a brief initial rise in gonadotrophins and then, with continued use, pituitary desensitisation and suppressed sex hormones; it is used in advanced prostate cancer, endometriosis and central precocious puberty.

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

    • established
      Claim: Leuprorelin missed its primary endpoint in spinal and bulbar muscular atrophy (JASMITT RCT) standing
    • resolved

    Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial.

    Katsuno M, Banno H, Suzuki K, Takeuchi Y, Kawashima M, Yabe I, Sasaki H, Aoki M, Morita M, Nakano I, Kanai K, Ito S, Ishikawa K, Mizusawa H, Yamamoto T, Tsuji S, Hasegawa K, Shimohata T, Nishizawa M, Miyajima H, Kanda F, Watanabe Y, Nakashima K, Tsujino A, Yamashita T, Uchino M, Fujimoto Y, Tanaka F, Sobue G, Japan SBMA Interventional Trial for TAP-144-SR (JASMITT) study group

    pmid 20691641

    • established
      Claim: Review of leuprorelin's pharmacology and uses in sex-hormone-related disorders standing
    • resolved

    Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

    Plosker GL, Brogden RN

    pmid 7533699

A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.